GleamWall
中文EN

CBIO CRESCENT BIOPHARMA, INC.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1253689 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-58.7%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-1,216.6%
Net margin-727.6%
FCF margin-549.5%
EBITDA margin-1,214.9%

Returns

ROE-55.8%
ROA-49.9%
ROIC (approx.)—
Asset turnover0.07x

Leverage & solvency

Liabilities / assets8.4%
Debt / equity0.00x
Current ratio12.57x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.75x
Accruals ratio-12.4%
Payout ratio—
Capex / revenue2.4%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$10.84M—
R&D expense$138.09M$14.26M
SG&A expense$25.39M$18.25M
Operating income-$152.63M-$40.04M
Interest expense$2.19M—
Pretax income-$151.94M—
Income tax$2.00M—
Net income-$153.94M-$37.88M
EBITDA-$152.55M-$40.00M
EPS (basic)—-0.59
EPS (diluted)—-0.59
Weighted avg. shares (diluted)—64.48M
Balance sheet
Cash & equivalents$213.19M$34.77M
Receivables$18.00M$0
Current assets$236.66M$34.80M
PP&E, net$846,000$0
Total assets$240.29M$35.62M
Current liabilities$36.07M$9.61M
Total liabilities$37.28M$47.10M
Shareholders' equity$203.01M-$15.48M
Shares outstanding27.56M1.02M
Cash flow statement
Operating cash flow-$71.53M-$31.10M
Capital expenditure$919,000$9,972
Free cash flow-$72.45M-$31.11M
Investing cash flow-$72.92M$20,028
Financing cash flow$322.98M$5,398
Depreciation & amortization$84,000$35,174
Stock-based compensation$13.30M$4.70M

Free plan shows the latest 2 periods; Pro shows all 14 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.